Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies - Wikidata - awgldk - TriplyDB

Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies

Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies

http://www.wikidata.org/entity/Q35405281

about

Lupus nephritis: the evolving role of novel therapeutics Altered Peripheral B-Lymphocyte Subsets in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects B cells and type 1 diabetes ...in mice and men.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse.Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens Transient depletion of B cells in young mice results in activation of regulatory T cells that inhibit development of autoimmune disease in adults Thinking bedside at the bench: the NOD mouse model of T1DM.Subcongenic analyses reveal complex interactions between distal chromosome 4 genes controlling diabetogenic B cells and CD4 T cells in nonobese diabetic mice.Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes.The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice.B-lymphocytes expressing an immunoglobulin specificity recognizing the pancreatic ß-cell autoantigen peripherin are potent contributors to type 1 diabetes development in NOD mice.Follicular B cells in thyroids of mice with spontaneous autoimmune thyroiditis contribute to disease pathogenesis and are targets of anti-CD20 antibody therapy.Genetic and Pharmacologic Models for Type 1 Diabetes.Autoimmune manifestations in aged mice arise from early-life immune dysregulation.In vivo detection of peripherin-specific autoreactive B cells during type 1 diabetes pathogenesis.Advances in our understanding of the pathophysiology of Type 1 diabetes: lessons from the NOD mouse.Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes.Bringing the human pancreas into focus: new paradigms for the understanding of Type 1 diabetes.B cell-targeted immunotherapy for type 1 diabetes: What can make it work?Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases Anti-serum with anti-autoantibody activity decreases autoantibody-positive B lymphocytes and type 1 diabetes of female NOD mice.CD19+CD24hiCD38hi regulatory B cells are associated with insulin resistance in type I Hashimoto's thyroiditis in Chinese females.The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development.Anti-CD20 Antibody Prevents Red Blood Cell Alloimmunization in a Mouse Model.Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy.Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice.Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction.Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development.Alternatives to steroids?! Beneficial effects of immunosuppressant drugs in autoimmune pancreatitis.

P2860

Q26998390-A154B055-FA2D-4E15-8588-E3A0E750D2CA Q30716607-E96B3BC9-31AC-466A-BAAE-DD04915EE63A Q33905411-BD6CDD18-E3E2-4973-A029-DEC4D61B888C Q33926306-14EE4B05-519D-4D96-B6DF-84195E5EB221 Q34583970-16F08BDD-6AC3-4941-BF38-E9C1CE78B5B7 Q34684829-C5BBA6EF-22B4-432F-9C1E-BE237AF253E6 Q34762482-90E452C8-60CC-4CA2-9116-F35277ED0B0A Q35852020-651A2E08-BE72-4DB7-BE65-CE06CA737E11 Q35911875-136D78A4-F2A6-4EAA-BB82-10087498ACDA Q36106586-EEE285C0-CBAB-47BD-B2E6-A8671A48A499 Q36330292-A646EC61-708E-43A4-B8B4-47C10221310C Q36587295-A8B23BFD-95B7-4FC8-B415-688FC0424062 Q37025666-A2CAF1E7-7565-41D3-92F1-86923E6913C3 Q37512037-A8182DFF-4DBF-4A95-8E7D-2C4A98D6140C Q37606821-DFF1E870-0712-4507-BB40-E1DAADF8A0C1 Q37624299-B2FB6D5D-7163-4581-9D83-B8B1BE379C04 Q37714655-6BA28D44-D962-4765-892F-213961FE76CE Q38135862-FA9FC116-6290-4C8A-B667-156420E98CA9 Q38688772-DA3F3A5C-8724-4BF1-9CB4-F55962ABA1E8 Q38692421-E9C41026-84C0-449D-9AEB-C69DC5F09743 Q38817783-832A9881-9782-4F7C-9941-88C82E0A307A Q39109245-DD64679C-7966-4286-9BC0-6D4143AF9701 Q41428260-04A96230-EEA3-4871-A752-9363A00CE56D Q42376346-24428F4B-EDEF-44A4-8254-85DBA685C880 Q44127971-0B7175D0-4AF9-4944-A6D9-79E9E74E834B Q47621588-6831C4D7-C750-4453-82CD-2312CE8D7157 Q47621604-3CD71DFF-A1DC-4932-9DC2-851DE0B566F6 Q51282774-A37E62C3-8E97-4FBF-90AF-871CC6434C28 Q51373243-EAE4DF5C-2972-4C2A-95CF-B5350482808C Q52430441-CBA6224A-1CBA-48FA-A549-10A719975A57 Q53109260-03E674EE-3850-4700-86C8-A87C52C4DAD9

P2860

Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies

http://www.wikidata.org/entity/Q35405281

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@ast

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@en

type

label

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@ast

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@en

prefLabel

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@ast

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@en

P1433

Q35405281-D0620FF9-47A9-4A68-8EA2-28CF81CABDD5

P1476

Q35405281-8A230DB7-9DB3-41B7-94B3-734EFB73E053

P2093

Q35405281-10182E39-580A-4AA7-97FE-5D76C46AD1A2

Q35405281-1123DD91-1907-4C54-B387-0981B4784081

Q35405281-40553014-1AC0-4A5B-ACB1-8EAACED09F6A

Q35405281-47BD278E-C769-462D-B709-4C2521EC4449

Q35405281-53C885E4-D748-4C12-B6C7-ECB12B7930D2

Q35405281-B9F1E955-CDED-481A-8319-AC06CB7B99FF

Q35405281-E9DE4477-E225-4AD2-9E76-8D54F5584B90

Q35405281-EA275CEB-FE75-4E52-A388-85FF924F8C69

Q35405281-FD03C231-591C-48F4-A430-7B6787629300

P2860

Q35405281-07F76A71-D075-4EF1-808B-0B7AB63378F2

Q35405281-0B5A782D-55FE-4773-8435-D39F99761452

Q35405281-0B60BF02-B20E-491A-9E2D-AAB553D55431

Q35405281-24E18B25-54AF-4305-A5BC-E41752782B97

Q35405281-2A774BBA-D4D2-4701-BE96-C172CDEB9573

Q35405281-387DEC57-B5B0-4B24-A236-5F41E2A83454

Q35405281-4C8764FD-3BD6-49F1-91E3-7F02E4C1620C

Q35405281-5A606B81-2D64-4E46-84DB-955AD3FD2237

Q35405281-86DC7878-222B-4A0F-BB5B-91EDBC0240E9

Q35405281-874BE3E3-166F-46BC-A2CA-79210A9BD01C

P304

Q35405281-81295B16-3F40-4A2C-84AB-EE897DCD8A69

P31

Q35405281-2C514A56-4763-4954-A0B0-B2A1965DBCEF

P356

Q35405281-84970AD8-FF67-4E78-94D7-72E115411B66

P407

Q35405281-979D3328-AE91-4003-BAF2-41A6E016B0D3

P433

Q35405281-36C55A0B-9711-450B-9311-A9D3B0317643

P478

Q35405281-E5BE1CD6-094B-4A06-95A0-7608F36A6FC9

P577

Q35405281-B0541AE9-CC94-412A-9F41-6A28EBF7399C

P5875

Q35405281-6E263A56-6A6C-435D-9820-0CCC4026D5FB

P698

Q35405281-A2C44BFC-913C-448E-9079-BC62B6625987

P921

Q35405281-3B72DE15-65E5-49B1-95F5-F91DF93E251E

P932

Q35405281-0391BC85-4AB9-425C-BF9B-FB7BF2FDBBD0

P356

P1433

P1476

Loss of intra-islet CD20 expre ...... cted type 1 diabetes therapies

@en

P2093

Clive Wasserfall

http://www.w3.org/2001/XMLSchema#string

David V Serreze

http://www.w3.org/2001/XMLSchema#string

Harold D Chapman

http://www.w3.org/2001/XMLSchema#string

John P Driver

http://www.w3.org/2001/XMLSchema#string

Marijke Niens

http://www.w3.org/2001/XMLSchema#string

Marilyn R Kehry

http://www.w3.org/2001/XMLSchema#string

Mark A Atkinson

http://www.w3.org/2001/XMLSchema#string

Michael Haller

http://www.w3.org/2001/XMLSchema#string

Robert Dunn

http://www.w3.org/2001/XMLSchema#string

P2860

Marginal zone B cells

Genetics of type 1 diabetes: what's next?

Genes within the Idd5 and Idd9/11 diabetes susceptibility loci affect the pathogenic activity of B cells in nonobese diabetic mice.

International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice.

Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues.

Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity.

Autoantibodies in diabetes.

B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice.

Invasion of the killer B's in type 1 diabetes.

Prediction and prevention of type 1 diabetes: progress, problems, and prospects.

P304

2914-2921

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB11-0705

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51650685

http://www.w3.org/2001/XMLSchema#string

P698

21926271

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3198088

http://www.w3.org/2001/XMLSchema#string